$846 | SAVE $149 | Single User
$1692 | SAVE $298 | Site License
$2121 | SAVE $374 | Global License

Malignant Melanoma: Update Bulletin
[Jan 2016]
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Jan 2016 | 296 | In Stock
Related Topics: FDA

Introduction

Introduction


Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’s (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy’s (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA’s approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma’s binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen’s newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.


Puchase Reasons


Key Questions Answered in this Update Bulletin:


  • Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?

  • To what extent will Keytruda be used as a first-line therapy for advanced melanoma?

  • Will Opdivo plus Yervoy’s superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?

  • What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?

  • How significantly will the need for patient monitoring impact Yervoy’s uptake in stage III melanoma?

  • How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


    Introduction


    Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’s (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy’s (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA’s approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma’s binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen’s newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.


    Puchase Reasons


    Key Questions Answered in this Update Bulletin:


  • Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?

  • To what extent will Keytruda be used as a first-line therapy for advanced melanoma?

  • Will Opdivo plus Yervoy’s superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?

  • What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?

  • How significantly will the need for patient monitoring impact Yervoy’s uptake in stage III melanoma?

  • How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

    Table of Contents
    for Malignant Melanoma: Update Bulletin [Jan 2016] [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    296 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Adult Malignant Glioma Global Clinical Trials Review, H2, 2018
    Adult Malignant Glioma Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial rep...
    25 Oct 2018 by Global Data USD $2,125 (normally
    USD $2,500)
    More Info
    SAVE 15% today! Malignant Pleural Mesothelioma - Pipeline Review, H2 2016
    Malignant Pleural Mesothelioma - Pipeline Review, H2 2016SummaryGlobal Markets Direct's latest Pharm...
    23 Nov 2016 by Global Markets Direct USD $1,700 (normally
    USD $2,000)
    More Info
    SAVE 15% today! Malignant Glioma Global Clinical Trials Review, H2, 2016
    Malignant Glioma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “...
    29 Jul 2016 by Global Data USD $2,125 (normally
    USD $2,500)
    More Info
    SAVE 15% today! Malignant Glioma Global Clinical Trials Review, H2, 2016
    Malignant Glioma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “...
    29 Jul 2016 by Global Data USD $2,125 (normally
    USD $2,500)
    More Info
    SAVE 15% today! Malignant Mesothelioma Global Clinical Trials Review, H1, 2016
    Malignant Mesothelioma Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial rep...
    29 Jun 2016 by Global Data USD $2,125 (normally
    USD $2,500)
    More Info
    SAVE 15% today! Malignant Mesothelioma Global Clinical Trials Review, H1, 2016
    Malignant Mesothelioma Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial rep...
    29 Jun 2016 by Global Data USD $2,125 (normally
    USD $2,500)
    More Info
    SAVE 15% today! Malignant Melanoma: Update Bulletin [April 2016]
    Introduction...Gain new KOL insights on the latest events happening in Malignant melanoma (MM): expa...
    01 Apr 2016 by FirstWord Pharma USD $846 (normally
    USD $995)
    More Info
    SAVE 15% today! Non Malignant pain Global Clinical Trials Review, H2, 2015
    Non Malignant pain Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report,...
    23 Dec 2015 by Global Data USD $2,125 (normally
    USD $2,500)
    More Info
    SAVE 15% today! Malignant Melanoma: KOL Insight
    IntroductionMalignant Melanoma: KOL Insight reveals the impact of immunotherapy on first-line treatm...
    01 Nov 2015 by FirstWord Pharma USD $6,715 (normally
    USD $7,900)
    More Info
    SAVE 15% today! Malignant Melanoma: KOL Insight
    IntroductionMalignant Melanoma: PD-1 inhibitors revolutionise treatment is a comprehensive report wi...
    17 Oct 2014 by FirstWord Pharma USD $6,715 (normally
    USD $7,900)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Malignant Melanoma: Update Bulletin [Jan 2016] [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...